The Molecular Mechanism and Therapeutic Progress in Glomus Tumor
Cancer Medicine · 2026-02 · 15 (2)
DOI: 10.1002/cam4.71588 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 15.02.2026. Verfasst von Zhi Cheng Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Glomus Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regional Projects of China Scholarship Council, National Natural Science Foundation of China, The HealthChina·BuChang ZhiYuan Public Welfare Projects for Heart and Brain Health under grant.
Abstract (Originalsprache)
Background
Glomus tumor (GT) is a rare mesenchymal neoplasm presumed to originate from the neuromyoarterial glomus body. Its pathogenesis is complex and involves alterations in multiple genes and signaling pathways. In the era of precision medicine, increased molecular research has begun to elucidate the oncogenic drivers of GT, offering novel potential directions for targeted treatment strategies.
Methods
This article provides a focused narrative review, synthesizing recent peer‐reviewed literature on the molecular genetics and clinical management of GT. Key findings from genetic studies, preclinical models, and clinical reports from recent years are summarized and analyzed.
Results
Molecular studies have identified recurrent genetic alterations underpinning GT pathogenesis. Key discoveries include frequent inactivating mutations in the NF1 gene, leading to constitutive RAS/MAPK pathway activation, and recurrent “MIR143‐NOTCH” gene fusions disrupting Notch signaling and so on. These drivers present potential therapeutic targets. While complete surgical excision remains the standard curative treatment for localized disease, molecular insights have spurred investigation into targeted agents, including MEK inhibitors for NF1‐deficient tumors and immunotherapy. Such systemic therapies are particularly relevant for multifocal, metastatic, or surgically challenging cases.
Conclusion
The integration of molecular profiling is refining the understanding of GT biology and expanding its therapeutic landscape. Moving beyond traditional surgery, the identification of targetable genetic alterations paves the way for personalized medicine approaches. Future efforts should focus on validating biomarkers in clinical trials to establish effective targeted therapies, ultimately improving outcomes for patients with complex or advanced GTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
ORCID-Profile: Zhi Cheng Jiang
Förderung
- Regional Projects of China Scholarship Council
- National Natural Science Foundation of China
- The HealthChina·BuChang ZhiYuan Public Welfare Projects for Heart and Brain Health under grant
- China General Program of Jiangxi Natural Science Foundation
- Jiangxi Provincial Health Commission Science and Technology grant
Zitieren
APA
Jiang, Z. C., Cheng, Z. J., Xiao, J. X., Huang, Y. Q., Ke, Z., Xu, J. H., Fu, X. K., & Huang, H. (2026). The Molecular Mechanism and Therapeutic Progress in Glomus Tumor. Cancer Medicine, 15(2). https://doi.org/10.1002/cam4.71588
Vancouver
Jiang ZC, Cheng ZJ, Xiao JX, Huang YQ, Ke Z, Xu JH, et al. The Molecular Mechanism and Therapeutic Progress in Glomus Tumor. Cancer Medicine. 2026;15(2). doi:10.1002/cam4.71588
BibTeX
@article{Jiang2026,
author = {Jiang, Zhi Cheng and Cheng, Zu Jue and Xiao, Jue Xian and Huang, You Quan and Ke, Zheng and Xu, Jing Hui and Fu, Xiang Kun and Huang, Hui},
title = {The Molecular Mechanism and Therapeutic Progress in Glomus Tumor},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {2},
doi = {10.1002/cam4.71588}
}
EUVIMED